On 30 October 2026, Sisram Medical Ltd. executed an on-market repurchase of 34,800 ordinary shares under the general mandate approved on 24 June 2026. The shares were bought at prices ranging between HKD 1.755 and HKD 1.82, with a volume-weighted average cost of HKD 1.7773 per share. Total consideration reached HKD 0.06 million.

Following the transaction, Sisram’s outstanding share count (excluding treasury shares) fell by 0.007 % to 467.56 million, while treasury shares rose to 783,200. The company’s total issued share capital remains unchanged at 468.34 million shares because the repurchased stock is being held in treasury rather than cancelled.

Since receiving the buyback mandate, Sisram has repurchased 783,200 shares—equivalent to 0.167 % of the shares outstanding on the mandate date—out of a maximum authority of 46.83 million shares. Under Hong Kong Stock Exchange rules, the company is restricted from issuing or selling treasury shares until 29 November 2026.